Nevro stock: buy or sell?
November 15th, 2019
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally.
Should I buy Nevro stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading strategy that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Nevro stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Nevro stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we collected 11 ratings published for NVRO stock in the last 30 days. The general sentiment of these ratings is bullish for NVRO stock, with 9 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-9||Bank of America||n/a||Buy|
|2019-8-9||Bank of America||n/a||Buy|
|2019-8-12||JMP Securities||n/a||Market Outperform|
|2019-5-13||Wells Fargo & Co||n/a||Outperform|
|2019-3-20||Wells Fargo & Co||Market Perform||Outperform|
|2019-3-20||Bank of America||Neutral||Buy|
|2019-2-22||BMO Capital Markets||Outperform||Market Perform|
Nevro stock analysis
After reaching all time highs on Nov 7th, Nevro stayed constant 0.20% yesterday to $105.19.
On Nov/7, NVRO hit new all time highs, pushing higher previous ATH of $106.93 recorded . New ATHs are usual entry points for many trading setups as there aren't higher resistences. Nevro stayed constant 0.20% to $105.19 after topping to all time highs on Nov 7th. On August NVRO price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock.
After boosting an outstanding 17.96% in a week last week, Nevro closed this week at $105.19 and stayed stable a lame -0.38%. Late September NVRO plunged a chilling -6.52% in just one week. This week broke a streak of 4 green weeks.
Not so far away is the last all-time high Nevro marked last week. Nevro stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since mid May when SMA20w and SMA40w crossed up, NVRO price gained $44.99 per share (74.73%). Since mid March when NVRO stock price broke up the SMA40w line, it gained $61.50 (140.76%).
Nevro stock price history
Nevro IPO was on November 6th, 2014 at $23.40 per share1. Since then, NVRO stock surged a 349.50%, with a yearly average of 69.90%. If you had invested $1,000 in Nevro stock in 2014, it would worth $3,495.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Nevro stock historical price chart
NVRO stock reached all-time highs on November 7th with a price of $108.20.
Nevro stock price target is $70.40Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' NVRO stock price predictions in the hope that they will be met as they may be wrong and not met. We found 8 price predictions for NVRO stock posted in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-9||Canaccord Genuity||Raises Target||$50.00||$59.00||18%|
|2019-8-9||Bank of America||Reiterates||$70.00||$74.00||5.7%|
|2019-8-9||Bank of America||Raises Target||$70.00||$74.00||5.7%|
|2019-5-13||Wells Fargo & Co||Reiterates||$75.00||$70.00||-6.7%|
|2019-5-10||Morgan Stanley||Lowers Target||$70.00||$64.00||-8.6%|
|2019-3-20||Bank of America||Upgrades||$50.00||$70.00||40%|
Financials and fundamental analysis
Earnings date and Earnings per ShareNevro reported amazing results for 2018-Q4 on February. Nevro rocketed Earnings per Share (EPS) by 88.20%, beating experts estimates of $-0.17. Nevro posted $-0.32.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Nevro annual sales rocketed an astounding 18.56% to $387.29 million USD from $326.67 marked in 2017. When comparing 2018 vs 2017, nonetheless, profit margin (that is, the net income divided by revenues) declined a -1.48% to -12.70%.
|2013||$24 M||-||$-26.17 M-111.4%||-|
|2014||$33 M||38.61%||$-30.68 M-94.2%||17.23%|
|2015||$70 M||113.69%||$-67.43 M-96.9%||119.79%|
|2016||$229 M||228.28%||$-31.78 M-13.9%||-52.87%|
|2017||$327 M||42.96%||$-36.66 M-11.2%||15.36%|
|2018||$387 M||18.56%||$-49.21 M-12.7%||34.23%|
Quarterly financial resultsNevro posted $107.94 M in revenues for 2018-Q4, a 12.88% up compared to previous quarter. Reported quarter earnings marked $-9.61 million with a profit margin of -8.90%. Profit margin appreciated a 2.88% compared to previous quarter when profit margin was -11.78%. When comparing revenues to same quarter last year, Nevro sales marked a superb growth and boosted a 10.19%.
|2017-Q1||$68 M||-||$-14.51 M-21.2%||-|
|2017-Q2||$78 M||14.00%||$-11.61 M-14.9%||-19.99%|
|2017-Q3||$82 M||5.43%||$-6.23 M-7.6%||-46.34%|
|2017-Q4||$98 M||19.10%||$-4.31 M-4.4%||-30.80%|
|2018-Q1||$88 M||-10.54%||$-17.71 M-20.2%||310.88%|
|2018-Q2||$96 M||9.64%||$-10.62 M-11.1%||-40.04%|
|2018-Q3||$96 M||-0.47%||$-11.27 M-11.8%||6.07%|
|2018-Q4||$108 M||12.88%||$-9.61 M-8.9%||-14.72%|
Nevro ownershipWhen you are planning to buy a company, it's always worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Nevro, 2.87% of all outstanding shares are owned by its staff.
Bearish positions for NVRO stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Nevro:
|Market cap||$3.3 B||$10.1 B||$65.8 B||$123.0 B|
|Total shares||31.0 M||45.2 M||115.6 M||401.0 M|
|Float shares||28.2 M||41.8 M||114.4 M||400.0 M|
|- Institutional holdings (%)||111.9%||89.8%||89.1%||90.7%|
|- Insider holdings (%)||2.9%||4.1%||1.0%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$104.52 - $106.07|
|Average true range||$4.29|
|50d mov avg||$87.93|
|100d mov avg||$79.62|
|200d mov avg||$68.42|
Nevro performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Nevro, the benchmark is made against ABIOMED, Intuitive Surgical and Thermo Fisher Scientific.
|TMOThermo Fisher Sci...||11.18%||17.38%||27.62%|